Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine, Mount Sinai, New YorkDr. Deepak L. Bhatt, an internationally recognized expert in cardiovascular medicine and interventional cardiology, is the Director of Mount Sinai Heart, in which capacity he heads the educational, research, and clinical cardiovascular work of the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System. He also serves as the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine
Prior to joining Mount Sinai, Dr. Bhatt was with Brigham and Women’s Hospital Heart and Vascular Center, where he served as Executive Director of Interventional Cardiovascular Programs, and Harvard Medical School, where he was Professor of Medicine. He served as Chief of Cardiology at VA Boston Healthcare from 2008 to 2013, and before that held a variety of leadership positions at Cleveland Clinic.
Dr. Bhatt has authored or co-authored over 2000 publications.
Disclosures
- Advisory boards: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys
- Board of directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock)
- Consultant: Broadview Ventures, Hims; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial)
- Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee)
- Other: Clinical Cardiology (Deputy Editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent)
- Research funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology
- Unfunded research: FlowCo
Recent Contributions to PracticeUpdate:
- ESC 2019: Recommendations From Dr. Deepak Bhatt
- Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids: From MESA
- P2Y12 Inhibitor Monotherapy Is Noninferior to Dual Antiplatelet Therapy After PCI
- Effect of 1-Month DAPT Followed by Clopidogrel vs 12-Month DAPT on Cardiovascular and Bleeding Events in Patients Receiving PCI
- Drug-Coated Balloon for Treatment of de Novo Coronary Artery Lesions in Patients With High Bleeding Risk
- Paclitaxel-Coated Balloon Angioplasty vs Drug-Eluting Stent in Acute MI
- Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation
- Anticoagulation for AFib After Percutaneous Coronary Intervention
- Dual Antiplatelet Therapy After PCI With Drug Eluting Stents
- Role of Triglycerides in Cardiac Disease